Among 2 analysts covering FibroGen (NASDAQ:FGEN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. FibroGen had 2 analyst reports since October 15, 2018 according to SRatingsIntel. Citigroup upgraded the stock to “Buy” rating in Wednesday, December 19 report. The rating was maintained by Leerink Swann on Monday, October 15 with “Outperform”. See FibroGen, Inc. (NASDAQ:FGEN) latest ratings:
19/12/2018 Broker: Citigroup Old Rating: Neutral New Rating: Buy New Target: $71 Upgrade
15/10/2018 Broker: Leerink Swann Old Rating: Outperform New Rating: Outperform Old Target: $82 New Target: $84 Maintain
Analysts expect Radcom Ltd. (NASDAQ:RDCM) to report $-0.33 EPS on February, 12.They anticipate $0.50 EPS change or 294.12% from last quarter’s $0.17 EPS. After having $0.05 EPS previously, Radcom Ltd.’s analysts see -760.00% EPS growth. The stock decreased 0.12% or $0.01 during the last trading session, reaching $8.25. About 8,532 shares traded. Radcom Ltd. (NASDAQ:RDCM) has declined 59.21% since February 7, 2018 and is downtrending. It has underperformed by 59.21% the S&P500. Some Historical RDCM News: 22/05/2018 – RADCOM 1Q EPS 2c; 14/05/2018 – Herald Investment Buys New 1.2% Position in Radcom; 11/05/2018 Russell Investments Group Exits Position in Radcom; 22/05/2018 – RADCOM LTD RDCM.O SEES FY 2018 REVENUE $43 MLN TO $47 MLN; 21/05/2018 – RADCOM Achieves Telefόnica UNICA Certification
More notable recent FibroGen, Inc. (NASDAQ:FGEN) news were published by: Nasdaq.com which released: “Analysis: Positioning to Benefit within Motorola Solutions, FibroGen, UnitedHealth Group, Newell Brands, Vuzix, and Choice Hotels International — Research Highlights Growth, Revenue, and Consolidated Results – Nasdaq” on January 17, 2019, also Investorplace.com with their article: “Mizuho: 7 Long-Term Value Stocks to Buy Now – Investorplace.com” published on January 15, 2019, Nasdaq.com published: “First Week of FGEN February 15th Options Trading – Nasdaq” on January 07, 2019. More interesting news about FibroGen, Inc. (NASDAQ:FGEN) were released by: Seekingalpha.com and their article: “Catabasis Pharmaceuticals: My Long Thesis And Analysis – Seeking Alpha” published on January 15, 2019 as well as Globenewswire.com‘s news article titled: “FibroGen Reports Second Quarter 2018 Financial Results Nasdaq:FGEN – GlobeNewswire” with publication date: August 07, 2018.
FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. The company has market cap of $4.89 billion. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It currently has negative earnings. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.
The stock increased 0.33% or $0.19 during the last trading session, reaching $57.52. About 416,474 shares traded. FibroGen, Inc. (NASDAQ:FGEN) has declined 13.72% since February 7, 2018 and is downtrending. It has underperformed by 13.72% the S&P500. Some Historical FGEN News: 31/05/2018 – ASTELLAS PHARMA INC – SAFETY PROFILE OF ROXADUSTAT WAS CONSISTENT WITH THAT OBSERVED IN PREVIOUS STUDIES BOTH IN DIALYSIS AND NON-DIALYSIS PATIENTS; 01/05/2018 – Imperas and Andes Extend Partnership, Delivering Models and Virtual Platforms for Andes RISC-V Cores with New AndeStar V5m; 28/03/2018 – Andes Technology Corp. to Present & Exhibit at Design & Reuse IP SOC Conference; 18/04/2018 – The Andes Summit: More Than Ayahuasca – A Re-Validation of the Cultural Heritage of Ecuador’s Ancient Indigenous Wisdom; 23/04/2018 – DJ FibroGen Inc, Inst Holders, 1Q 2018 (FGEN); 21/05/2018 – FIBROGEN: PAMREVLUMAB SLOWED IPF DISEASE PROGRESSION IN STUDY; 31/05/2018 – ASTELLAS & FIBROGEN ANNOUNCE TOPLINE RESULTS FROM DOUBLE-BLIND JAPAN PHASE 3 STUDY FOR ROXADUSTAT IN HEMODIALYSIS CHRONIC KIDNEY DISEASE PATIENTS WITH ANEMIA; 21/05/2018 – FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at American Thoracic Society 2018; 13/03/2018 Announcing The First Andes Summit – Indigenous Wisdom-Keepers to Gather With People of The North to lnitiate a New Commitment to Earth Healing; 31/05/2018 – ASTELLAS PHARMA INC – ROXADUSTAT WAS WELL TOLERATED IN STUDY